A5026896662- Mechanical Circulatory Support Devices
- Transplantation: Methods and Outcomes
- Cardiac Structural Anomalies and Repair
- Congenital Heart Disease Studies
- Renal Transplantation Outcomes and Treatments
- Cardiac Arrest and Resuscitation
- Organ Transplantation Techniques and Outcomes
- Cardiac pacing and defibrillation studies
- Congenital heart defects research
- Heart Failure Treatment and Management
- Cardiomyopathy and Myosin Studies
- Vascular anomalies and interventions
- Viral Infections and Immunology Research
- Polyomavirus and related diseases
- Cardiac Ischemia and Reperfusion
- Pulmonary Hypertension Research and Treatments
- Blood disorders and treatments
- Atrial Fibrillation Management and Outcomes
- SARS-CoV-2 and COVID-19 Research
- Acute Myocardial Infarction Research
- Streptococcal Infections and Treatments
- Heparin-Induced Thrombocytopenia and Thrombosis
- Cardiovascular Effects of Exercise
- Drug-Induced Adverse Reactions
- Rabies epidemiology and control
Children's Hospital of Pittsburgh
2016-2025
University of Pittsburgh
2018-2024
University of Pittsburgh Medical Center
2016-2021
Children's Hospital of Michigan
2014
In-Q-Tel
2014
Endomyocardial biopsy (EMB) is costly and discomforting yet remains a key component of surveillance after pediatric heart transplantation (HT). Donor-derived cell-free DNA (dd-cfDNA) has been histologically validated with high negative predictive value, offering an alternative to EMB (sEMB).We implemented protocol using commercially available dd-cfDNA assays in place sEMB HT. Recipients ≧7 months post-HT reassuring clinical assessment were referred for dd-cfDNA. When not elevated above the...
US Pediatric Heart Allocation Policy was recently revised, deprioritizing candidates with cardiomyopathy while maintaining status 1A eligibility for congenital heart disease (CHD) on "high-dose" inotropes. We compared waitlist characteristics and mortality around this change. Status listings decreased (70% to 56%, P < .001) CHD representation increased among (48% vs 64%, .001). Waitlist overall (subdistribution hazard ratio [SHR] 0.96, = .63) (SHR 1.16, .14) were unchanged. trended better...
Abstract Background Endomyocardial biopsy (EMB)‐led surveillance is common after pediatric heart transplantation (HT), with some centers performing periodic EMBs indefinitely HT. Donor derived cell‐free DNA (dd‐cfDNA)‐led offers an alternative, but knowledge about its clinical and economic outcomes, both key drivers of potential utilization, are lacking. Methods Using single‐center recipient center‐level data, we describe outcomes prior to since transition from EMB‐led dd‐cfDNA‐led young...
Abstract Data are lacking on RSB intensity and outcomes after pediatric heart transplantation. PHTS centers received a survey practices from 2005 to present. data were obtained for 2010‐2013 integrated with center‐matched responses analysis. Survey response rate was 82.6% (38/46). Centers classified as low‐, moderate‐, high‐intensity programs based frequency (0—more than 8 /y). decreased increasing time HT. Age at HT impacted mostly in year 1, little no impact later years. Most have not...
Data are limited on the efficacy and safety of bortezomib for treatment AMR following OHT pediatric acquired or CHD. Retrospective chart review identified patients who received acute (n = 3, within two wk diagnosis) chronic 1, three months after as part a desensitization regimen 1). Bortezomib was associated with 3-66% reduction in class I DSA 7-82% II DSA. Two cases resolved by first follow-up biopsy. resolution currently well. One patient developed second episode AMR, which unresponsive to...
Despite increasing utilization of continuous-flow pediatric ventricular assist devices (VAD) in children, data on exercise testing and cardiac rehabilitation (CR) are unknown. We described variation CR practices identified barriers to CR. A survey was performed through the Advanced Cardiac Therapies Improving Outcomes Network (ACTION) representing VAD centers across North America. Descriptive statistics were performed. multidisciplinary cohort 52 respondents from 28 responded. Although 38%...
Third-dose mRNA COVID-19 vaccine is currently recommended in the United States for SOT recipients based part on data showing diminished immune response, including Ab production, after a two-dose regimen. Data response adolescent and young adult are limited, no reported third-dose responsiveness.Results of serologic testing convenience sample 28 vaccinated HT at single institution were collected from medical record summarized.At median 98.5 days (IQR 59-150) second dose, 17 (61%) had an...
Mutations in cardiac genes are one of the primary causes infantile cardiomyopathy. In this study, we report genetic findings two siblings carrying variations MYBPC3 and SMYD1 genes. The first patient is a female proband exhibiting hypertrophic cardiomyopathy (HCM) biventricular heart failure truncating homozygous variant c.1224-52G>A (IVS13-52G>A) novel (c.302A>G; p.Asn101Ser) gene. second patient, proband’s sibling, male infant diagnosed with carries same variant. While specific...
Ventricular assist device (VAD) use for failed stage II palliation (S2P) is increasing with limited data on outcomes. To address this knowledge gap, we conducted a multicenter retrospective review of the Advanced Cardiac Therapies Improving Outcomes Network registry. We leveraged registry to analyze clinical course, complications, and survival systemic VADs (SVAD) after S2P. identified 34 patients from 15 centers between 2012 2022 implanted at median age 1.8 years [interquartile range (IQR)...
Introduction: Cell cycle entry and division of differentiated heart muscle cells (cardiomyocytes, CMs) is the evolutionarily conserved mechanism development regeneration. Quantification CM proliferation in humans a critical step towards developing new regenerative therapies for failure. To provide definitive evidence to characterize generated phenotypes humans, we implemented research approach using 15 N-thymidine administration mark S-phase. Tetralogy Fallot (ToF) most common cyanotic...
Background We have developed a new clinical research approach for the quantification of cellular proliferation in human infants to address unanswered questions about tissue renewal and regeneration. The consists oral 15 N-thymidine administration label cells S-phase, followed by Multi-isotope Imaging Mass Spectrometry detection incorporated cell nuclei. To establish approach, we performed an observational study examine uptake elimination N-thymidine. compared at-home with in-hospital...